Skip to main content

Table 1 Patient Characteristics (Open-Label Baseline, Safety Population)

From: Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study

Characteristic

LUR-LURa (N = 136)

RIS-LURb (N = 87)

Male, n (%)

102 (75.0)

58 (66.7)

Age, mean (SD), y

43.9 (10.7)

42.8 (10.8)

Race, n (%)

 White

50 (36.8)

39 (44.8)

 Black

67 (49.3)

40 (46.0)

 Asian

6 (4.4)

1 (1.1)

 Other

13 (9.6)

7 (8.0)

Ethnicity, Hispanic/Latino, n (%)

36 (26.5)

25 (28.7)

Duration of illness, mean (SD), y

16.9 (10.7)

17.6 (11.9)

≥4 hospitalizations, n (%)

30 (22.1)

25 (28.8)

PANSS total score, mean (SD)

55.4 (13.6)

55.5 (11.2)

CGI-S score, mean (SD)

2.8 (0.8)

2.9 (0.8)

MADRS score, mean (SD)

5.1 (5.6)

4.3 (4.4)

  1. CGI-S Clinical Global Impression-Severity Scale, LUR lurasidone, MADRS Montgomery-Åsberg Depression Rating Scale, PANSS Positive and Negative Syndrome Scale, RIS risperidone, SD standard deviation
  2. a Patients who received lurasidone in both double-blind and open-label studies
  3. b Patients who received risperidone during the double-blind study and were switched to lurasidone in the open-label study